At a glance
- Matrixyl (palmitoyl pentapeptide-4) is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 33 publications mentioning it, including 2 randomized controlled trials and 2 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA's adverse event system (FAERS) holds 1 report mentioning it; 1 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Peptides in Aesthetic Dermatology: Classification, Fibroblast-Centered Mechanisms, Delivery Technologies, and Clinical Evidence.
- Permeation behaviour of cosmetic actives into the human stratum corneum.
- Use of a Serum With the Infinite Glow® Device Improves Signs of Facial Aging: A Split-Face Case Report Using VISIA Analysis.
- Nanostructure and Collagen-Stimulating Activity of Cationic Pentapeptide Lipopeptides.
- A framework for the safety evaluation of peptides in cosmetics.
- Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study.
- Bioactive Glycyrrhizic Acid Ionic Liquid Self-Assembled Nanomicelles for Enhanced Transdermal Delivery of Anti-Photoaging Signal Peptides.
- Dually functionalized dendrimer for stimuli-responsive release of active ingredients into the skin.
- Self-Assembly and Wound Healing Activity of Biomimetic Cycloalkane-Based Lipopeptides.
- Mesenchymal stem cell therapy using Pal-KTTKS-enriched carboxylated cellulose improves burn wound in rat model.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 1
- Serious
- 1
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.